SCHEMBL305026

SCHEMBL305026

CCOC(=O)/C=C/c1ccccc1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.47
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
HSD17B1 P14061 1/20 0.39
HSD17B2 P37059 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 2/20 0.39
CYP3A4 P08684 2/20 0.39
HTT P42858 1/20 0.39
NR1I2 O75469 1/20 0.39
PGR P06401 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603145 0.87 BACE1 (0.51) BACE1CA1CA2HTTTBXAS1
SCHEMBL4603138 0.87 BACE1 (0.51) BACE1CA1CA2HTTTBXAS1
SCHEMBL9526448 0.85 KDM4E (0.39) BACE1CA12CA1CA2CA7
SCHEMBL21507145 0.85 BACE1 (0.64) BACE1CA12CA1CA2CA7
SCHEMBL306003 0.82 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL9526496 0.79 KDM4E (0.35) BACE1NPC1RAB9AMAPTLMNA
SCHEMBL875044 0.78 BACE1 (0.39) BACE1LMNACYP3A4HTTALDH1A1
SCHEMBL7836085 0.78 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL7836087 0.78 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL305028 0.77 BACE1 (0.39) BACE1TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS CHIKAUCHI KEN (JP) 2012-03-22 US disclosed
US-8093294-B2 Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2012-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071457-A1 METALLO-BETA-LACTAMASE INHIBITORS ME1, MGAM, GAA BACE1 59/4885CA12 909/4885CA1 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.